Navigating The Challenges Of Early Drug Development—How To Avoid Common Pitfalls

This webinar will use real-world case histories to identify common pitfalls in the early stages of drug development programs, offering practical strategies to help you avoid unnecessary delays and costly rework. Effective drug development relies on seamless collaboration among multiple disciplines and clear communication between sponsors and contract research organizations (CROs). As a CRO, Altasciences understands the critical role of shared information in ensuring success. The session will provide essential insights and considerations for initiating a new drug development program, illustrated through instructive examples.

Key topics include planning strategies to prevent delays and rework, the value of open communication between sponsors and CROs, and lessons learned from real case studies. This webinar is designed for nonclinical and clinical scientists, project directors, and senior biotech executives seeking to optimize their development pathways.

The presentation will feature two experienced leaders in drug development. Dr. Norbert Makori, Vice President of Toxicology at Altasciences, brings over 20 years of expertise as a general and reproductive toxicologist, including leadership roles at major CROs. A Diplomate of the American Board of Toxicology (DABT) with a PhD in comparative pathology, Dr. Makori has a proven track record in guiding complex projects. Joining him is Dr. Hazel Clay, Drug Development Advisor at Altasciences, who has over 30 years of experience in supporting innovative pharmaceutical assets. Dr. Clay has held key positions at Labcorp, including Executive Director of Science and Strategy for Early Phase Development Solutions, and was instrumental in creating programs to accelerate sponsors through first-in-human studies. Together, they will share actionable insights to streamline your drug development process.